[{"id":"c9d1a579-ede0-4060-a970-738063622323","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654716","created_at":"2021-01-18T17:56:08.387Z","updated_at":"2025-02-25T14:40:01.342Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","source_id_and_acronym":"NCT03654716","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • MDM2 • TET2 • SMARCB1 • PPM1D","pipe":" | ","alterations":" TP53 wild-type • TET2 mutation","tags":["TP53 • MDM2 • TET2 • SMARCB1 • PPM1D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2025-02-14"},{"id":"02fe09dd-fb6d-428c-8c55-0af77e346e1c","acronym":"PTCL13","url":"https://clinicaltrials.gov/study/NCT02223208","created_at":"2025-02-26T10:03:50.822Z","updated_at":"2025-02-26T10:03:50.822Z","phase":"Phase 1/2","brief_title":"Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas","source_id_and_acronym":"NCT02223208 - PTCL13","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" TET2","pipe":" | ","alterations":" TET2 mutation","tags":["TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-12-09"},{"id":"da609c24-a157-41fa-ac07-47f23b043f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06517511","created_at":"2025-02-26T12:22:33.668Z","updated_at":"2025-02-26T12:22:33.668Z","phase":"Phase 2","brief_title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","source_id_and_acronym":"NCT06517511","lead_sponsor":"Sun Yat-sen University","biomarkers":" TET2 • PTPN2 • DDX3X","pipe":"","alterations":" ","tags":["TET2 • PTPN2 • DDX3X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/11/2024","start_date":" 07/11/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-07-24"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"99f1535a-a07e-4728-99bf-fde0b1c35e59","acronym":"","url":"https://clinicaltrials.gov/study/NCT03433781","created_at":"2021-01-18T16:56:15.881Z","updated_at":"2024-07-02T16:35:12.574Z","phase":"Phase 1/2","brief_title":"A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations","source_id_and_acronym":"NCT03433781","lead_sponsor":"NYU Langone Health","biomarkers":" TET2","pipe":" | ","alterations":" TET2 mutation","tags":["TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 11/06/2022","primary_completion_date":" 11/06/2022","study_txt":" Completion: 05/16/2023","study_completion_date":" 05/16/2023","last_update_posted":"2024-03-27"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"abf80572-9487-4b72-b314-93907c37e4e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01904136","created_at":"2021-01-18T08:34:33.209Z","updated_at":"2024-07-02T16:35:22.380Z","phase":"Phase 1/2","brief_title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT01904136","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 04/22/2014","start_date":" 04/22/2014","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2024-01-24"},{"id":"8f3a4a5a-f465-4be9-88b8-05e3ac3cf7a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05577364","created_at":"2023-12-14T18:18:10.664Z","updated_at":"2024-07-02T16:35:26.238Z","phase":"Phase 1/2","brief_title":"Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients","source_id_and_acronym":"NCT05577364","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • PD-1 • TET2 • LAG3 • CTLA4 • PTPN2 • DDX3X","pipe":" | ","alterations":" TET2 mutation • PTPN2 mutation","tags":["PD-L1 • PD-1 • TET2 • LAG3 • CTLA4 • PTPN2 • DDX3X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation • PTPN2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor) • vincristine • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2023-12-14"},{"id":"e83462de-87f7-4dab-90df-3962b5abd242","acronym":"","url":"https://clinicaltrials.gov/study/NCT01823198","created_at":"2021-01-18T08:06:03.874Z","updated_at":"2024-07-02T16:35:30.156Z","phase":"Phase 1/2","brief_title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","source_id_and_acronym":"NCT01823198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Proleukin (aldesleukin) • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2023-11-07"},{"id":"57d644a2-7988-4d7c-b469-e62a58aafbfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02960646","created_at":"2021-01-18T14:32:35.822Z","updated_at":"2024-07-02T16:35:55.351Z","phase":"Phase 1","brief_title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02960646","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement","tags":["FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 02/13/2023","primary_completion_date":" 02/13/2023","study_txt":" Completion: 02/13/2023","study_completion_date":" 02/13/2023","last_update_posted":"2023-02-16"},{"id":"7d0269ef-d62a-464e-b888-7fb2fa28d120","acronym":"","url":"https://clinicaltrials.gov/study/NCT05250362","created_at":"2022-02-22T13:52:32.086Z","updated_at":"2024-07-02T16:36:15.354Z","phase":"Phase 1/2","brief_title":"Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT05250362","lead_sponsor":"Sichuan University","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr del(7q)","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"d2faf2b9-af61-4fac-b07d-98cf26f0e769","acronym":"","url":"https://clinicaltrials.gov/study/NCT03397173","created_at":"2021-01-18T16:45:54.032Z","updated_at":"2024-07-02T16:36:26.502Z","phase":"Phase 2","brief_title":"TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid","source_id_and_acronym":"NCT03397173","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" FLT3 • TET2","pipe":" | ","alterations":" TET2 mutation","tags":["FLT3 • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 01/03/2021","primary_completion_date":" 01/03/2021","study_txt":" Completion: 01/21/2021","study_completion_date":" 01/21/2021","last_update_posted":"2021-08-11"},{"id":"73e97b9d-0254-43f8-997d-ea880735e4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311815","created_at":"2021-01-18T16:21:28.250Z","updated_at":"2024-07-02T16:36:34.554Z","phase":"","brief_title":"Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03311815","lead_sponsor":"PETHEMA Foundation","biomarkers":" KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2","pipe":" | ","alterations":" U2AF1 mutation","tags":["KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e U2AF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 900","initiation":"Initiation: 10/06/2017","start_date":" 10/06/2017","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2021-02-16"},{"id":"8e772c5c-efa1-43b0-a436-6535ec330b7b","acronym":"PMF/ET-FLT","url":"https://clinicaltrials.gov/study/NCT03116542","created_at":"2021-01-18T15:21:18.891Z","updated_at":"2024-07-02T16:36:40.562Z","phase":"","brief_title":"18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia","source_id_and_acronym":"NCT03116542 - PMF/ET-FLT","lead_sponsor":"Hamad Medical Corporation","biomarkers":" IDH1 • IDH2 • JAK2 • SF3B1 • ASXL1 • TET2 • SRSF2 • CALR","pipe":"","alterations":" ","tags":["IDH1 • IDH2 • JAK2 • SF3B1 • ASXL1 • TET2 • SRSF2 • CALR"],"overall_status":"Unknown status","enrollment":" Enrollment 21","initiation":"Initiation: 05/07/2017","start_date":" 05/07/2017","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2020-09-29"},{"id":"8e9f015e-2f49-43b1-ac27-09c787f2c5c6","acronym":"AZALENA","url":"https://clinicaltrials.gov/study/NCT02472691","created_at":"2021-01-18T11:54:11.739Z","updated_at":"2025-02-25T14:35:40.382Z","phase":"Phase 2","brief_title":"Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT","source_id_and_acronym":"NCT02472691 - AZALENA","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" FLT3 • ASXL1 • TET2 • WT1","pipe":" | ","alterations":" FLT3 mutation • ASXL1 mutation • TET2 mutation","tags":["FLT3 • ASXL1 • TET2 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • ASXL1 mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2020-05-28"},{"id":"5468a9ed-3939-4136-ba65-8af18e922582","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771222","created_at":"2021-01-18T18:39:29.431Z","updated_at":"2024-07-02T16:37:04.706Z","phase":"Phase 2","brief_title":"Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies","source_id_and_acronym":"NCT03771222","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" TP53 • FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3-ITD mutation • DNMT3A mutation • TET2 mutation","tags":["TP53 • FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • DNMT3A mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-13"},{"id":"f887d510-0878-4a46-85d9-281df4450717","acronym":"AMICUS","url":"https://clinicaltrials.gov/study/NCT02804984","created_at":"2021-01-18T13:45:14.737Z","updated_at":"2024-07-02T16:37:08.315Z","phase":"","brief_title":"Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance","source_id_and_acronym":"NCT02804984 - AMICUS","lead_sponsor":"Centre Hospitalier Universitaire, Amiens","biomarkers":" KRAS • IDH1 • IDH2 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • U2AF1 • GATA2 • ZRSR2","pipe":"","alterations":" ","tags":["KRAS • IDH1 • IDH2 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • U2AF1 • GATA2 • ZRSR2"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2018-08-03"}]